Active Ingredient History
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone. Ergoalcifediol is used for use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis). Ergocalciferol is manufactured and marketed under various names, including Deltalin (Eli Lilly and Company), Drisdol (Sanofi-Synthelabo) and Calcidol (Patrin Pharma). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypoparathyroidism (approved 2009)
Hypophosphatemia, Familial (approved 2009)
Rickets (approved 2009)
Anemia (Phase 4)
Arthritis, Rheumatoid (Phase 4)
Bariatric Surgery (Phase 2)
Bone Diseases (Phase 4)
Breast Neoplasms (Phase 3)
Burns (Phase 2)
Cardiovascular Diseases (Phase 2)
Chronic Pain (Phase 2)
COVID-19 (Phase 3)
Cystic Fibrosis (Phase 2)
Death, Sudden, Cardiac (Phase 2)
Dental Caries (Phase 4)
Dermatology (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2/Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Ergocalciferols (Phase 4)
General Surgery (Phase 2)
Healthy Volunteers (Phase 3)
Hepcidins (Phase 4)
Hip Fractures (Phase 4)
Hypercalciuria (Phase 4)
Hyperparathyroidism, Secondary (Phase 4)
Inflammation (Phase 1)
Insulin Resistance (Phase 1)
Iron Deficiencies (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Malabsorption Syndromes (Early Phase 1)
Malnutrition (Phase 4)
Multiple Trauma (Phase 1/Phase 2)
Musculoskeletal Diseases (Phase 1/Phase 2)
Musculoskeletal Pain (Phase 2)
Nephrolithiasis (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 3)
Obesity (Phase 4)
Overweight (Phase 4)
Penile Induration (Phase 1)
Pregnancy Complications (Phase 3)
Pruritus (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Sarcoidosis (Phase 4)
Signs and Symptoms (Phase 4)
Urolithiasis (Phase 4)
Vitamin D (Phase 4)
Vitamin D Deficiency (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
